Clinical Trial Detail

NCT ID NCT02993731
Title A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma (CanStem111P)
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Boston Biomedical, Inc
Indications

pancreatic ductal adenocarcinoma

Therapies

Gemcitabine + Nab-paclitaxel + Napabucasin

Gemcitabine + Nab-paclitaxel

Age Groups: adult senior

No variant requirements are available.